Indicaciones de quimioterapia en cáncer de mama

Boletín epidemiológico semanal. Centro Nacional de Epidemiología 1999. Vol. 7 Nº 16/169-176. Fisher, 1992, The evolution of paradigms for the management of breast cancer; a personal perspective, Cancer Res, 52, 2371 1992, Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31000 recurrences and 24000 deats among 75000 women, Lancet, 339, 1 1998, Polychemotherapy for early breast cancer: an overview of randomised trials, Lancet, 352, 930, 10.1016/S0140-6736(98)03301-7 Fisher, 1996, J Clin Oncol, 14, 1982, 10.1200/JCO.1996.14.7.1982 Mansour, 1998, Survival advantage of adyuvant chemotherapy in high-risk node-negative breast cancer: ten-year analisys an intergroup study, J. Clin. Oncol, 16, 3486, 10.1200/JCO.1998.16.11.3486 Fisher, 1997, Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer, J. Natl. Cancer Inst., 89, 1673, 10.1093/jnci/89.22.1673 1985, Consensus Conference: Adyuvant Chemotherapy for Breast Cancer, Jama, 254, 3461, 10.1001/jama.1985.03360240073038 1991, NHI Consensus Conference: Treatment of Early Stage Breast Cancer, Jama, 265, 391, 10.1001/jama.1991.03460030097037 Adjuvant therapy for breast cancer. National Institutes of Health. Consensus Development Conference Statement. Nov 1-3, 2000. http.//odp.od.nih. gov/consensus/ cons/114/114_statement.htm. Glick, 1992, Meeting highlights: Adjuvant therapy for breast cancer, J Nat Cancer Inst, 84, 1479, 10.1093/jnci/84.19.1479 Goldhrirsch, 1995, Meeting highlights: International Consensus Panel on The treatment of primary breast cancer, J Natl Cancer Inst, 87, 1441, 10.1093/jnci/87.19.1441 Goldhirsch, 1990, Meeting highlights: International Consensus Panel on the treatment of primary breast cancer. VI International Consensus Conference on Primary Treatment of the breast, J. Natl. Cancer Inst, 1998,, 21, 1601 1988, Combination adjuvant chemotherapy for node-positive breast cancer: Inadecuaty of a single perioperative cicle, N Eng J Med, 319, 677, 10.1056/NEJM198809153191104 1998, Tamoxifen for early breast cancer: an overview of the randomised trials, Lancet, 351, 1451, 10.1016/S0140-6736(97)11423-4 Clahsen, 1996, Improved local control and disease-free survival after perioperative chemotherapy for early-stage breast cancer: A European Organization for Research and Treatment of Cancer Breast. Cancer Cooperative Group Study, J Clin. Oncol, 14, 745, 10.1200/JCO.1996.14.3.745 Moliterni, 1991, Cyclophosphamide, methotrexate, and fluorouracil with and without doxorrubicin in the adyuvant treatment of resec-table breast cancer with one to three positive axillary nodes, J. Clin. Oncol, 9, 1124, 10.1200/JCO.1991.9.7.1124 Bonadonna, 1995, Sequential or alternating doxorubicin and CMF regimen in breast cancer with more than three positive nodes. Ten-years results, Jama, 273, 5472, 10.1001/jama.1995.03520310040027 Fisher, 1990, J Clin. Oncol, 8, 1483, 10.1200/JCO.1990.8.9.1483 Thor, 1998, erbB-2, p-53, and efficacy of adjuvant therapy in lymph node-positive breast cancer, J Natl. Cancer Inst, 90, 1346, 10.1093/jnci/90.18.1346 Paik, 1998, erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer, J. Natl. Cancer Inst, 90, 1361, 10.1093/jnci/90.18.1361 Budman, 1998, For the Cancer and Leukemia Group B. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer, J. Natl. Cancer Inst, 90, 1205, 10.1093/jnci/90.16.1205 Hryniuk, 1996, Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer, J. Clin. Oncol, 4, 1162, 10.1200/JCO.1986.4.8.1162 Wood, 1994, Dose and intensity of adjuvant chemotherapy for stage II, node-positive breast cancer, N Eng J Med, 330, 1253, 10.1056/NEJM199405053301801 Budman, 1998, Dose an Dose Intensity as determinants of outcome in the adjuvant treatment of breast cancer, J Natl. Cancer Inst., 90, 1205, 10.1093/jnci/90.16.1205 Fisher, 1997, Mamounas: Increased intensification and total dose of ciclophosphamide in a doxorubicin-ciclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Proyect B-22, J Clin. Oncol.,, 15, 1858, 10.1200/JCO.1997.15.5.1858 Fisher, 1999, Further evaluation of intensified and increased total dose of ciclop-hosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Proyect B-25, J. Clin. Oncol.,, 17, 3374, 10.1200/JCO.1999.17.11.3374 Peter WP, Cancer and Leukemia Group B:NCI High Priority Clinical Trial. Phase III Randomized Comparation of High-dose Chemotherapy with Autologous Marrow and Peripheral Stem Cell Support vs Standard-Dose Chemotherapy Following Adjuvant Chemotherapy in Women with Stage II/IIIA Breast Cancer with at Least 10 Positive Axillary Nodes (Summary Last Modified 09/98), CLB-9082, clinical trials, closed, 05/29/1998. Tallman MS, Eastern Cooperative Oncology Group: NCI High Priority Clinical Trials. Phase III Randomized Study of Adjuvant CAF (Cyclophosphamide/Doxorubivin/Fluorouracil) vs Adjuvant CAF Followed by Intensification with High-Dose Cyclophosphamide/thiotepa plus Autologous Stem Cell Rescue in Women with Stage II/III Breast Cancer At High Risk of Recurrence (Summary Last Modified 12/98), Est-2190, clinical trials, closed, 08/03/1998. Peters W, Rosner G, et al. For CALGB, SWOG, and NCIC: A prospective randomized comparation of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Pro Am Soc Clin Oncol, 1999;2a(3). The Scandinavian Breast Cancer Study Group 9401: Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autogous bone marrow stem cell versus dose escalated and tailored FEC therapy. Pro Am Soc Clin Oncol, 1999;2a(3). Rodenhuis, 1998, Randomized trial of high-dose chemotherapy with autologous stem cell recue for breast cancer with extensive axillary lymph-node involvement, Lancet,, 352, 515, 10.1016/S0140-6736(98)01350-6 David, 2000, High-dose chemotherapy positive in breast-cancer trial, Lancet, 355, 1973, 10.1016/S0140-6736(05)72909-3 Fisher, 1996, J Clin. Oncol.,, 14, 1982, 10.1200/JCO.1996.14.7.1982 Henderson IC, Berry D, Demetri G, Cirrincione C; Goldstein L; Martino S; et. al.: Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer. Proc Am Soc Clin Oncol, 1998;101a (390a). Ueno, 1997, D, Anderson Cancer Center. Cancer Chemotherapy and Pharmacology,, 40, 321, 10.1007/s002800050664 Berg, 1994, Results of concomitantly administered chemoradiation for locally advanced non inflammatory breast cancer, Seminars in Radiation Oncology,, 4, 226, 10.1016/S1053-4296(05)80093-1 Fisher, 1998, De Wys: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer, J Nat Cancer Inst, 16, 2672 Kuukasjarvi, 1996, Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy, J. Clin. Oncol, 14, 2584, 10.1200/JCO.1996.14.9.2584 Perry, 1987, Chemohormonal therapy in advanced carcinoma of the breast: Cancer and Leukemia Group B protocol 8081, J Clin. Oncol.,, 5, 1534, 10.1200/JCO.1987.5.10.1534 Honig, 1996, Hormonal therapy and chemotherapy, 669 Greenberg, 1996, Log-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer, J Clin. Oncol.,, 14, 2197, 10.1200/JCO.1996.14.8.2197 Ranson, 1997, Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial, J. Clin. Oncol, 15, 3185, 10.1200/JCO.1997.15.10.3185 Blumm, 1999, Multicenter phase II study of capecitabine in paclitaxel-refractory metastasic breast cancer, J. Clin. Oncol., 17, 485, 10.1200/JCO.1999.17.2.485 Degardin, 1994, Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer, Ann. Oncol.,, 5, 423, 10.1093/oxfordjournals.annonc.a058873 Carmichael, 1997, Advanced breast cancer: investigational role of gemcitabine, European Journal of Cancer, 33, S27, 10.1016/S0959-8049(96)00392-9 Tranum, 1982, Adriamicin combinations in advanced breast cancer: a Southwest Oncology Group study, Cancer, 49, 835, 10.1002/1097-0142(19820301)49:5<835::AID-CNCR2820490502>3.0.CO;2-Z Misset, 1999, Dose-finding study of docetaxel and doxorubicin in firts-line treatment of patients with metastatic breast cancer, Ann Oncol, 10, 553, 10.1023/A:1026418831238 Buzdar, 1989, Hortobagy: Ten year results of FAC adjuvant chemotherapy trial in breast cancer, Am. J. Clin. Oncol, 12, 123, 10.1097/00000421-198904000-00007 Tormey, 1982, De Wys,: Comparison of induction chemotherapies for metastatic breast cancer: an Eastern Cooperative Oncology Group Trial, Cancer, 50, 1235, 10.1002/1097-0142(19821001)50:7<1235::AID-CNCR2820500703>3.0.CO;2-L Nabholtz, 1996, Multicenter randomized comparative study of two doses of paclitaxel in patients with metas-tatic breas cancer, J Clin Onc, 14, 1858, 10.1200/JCO.1996.14.6.1858 Nabholtz, 1997, Taxotere (T) versus Mytomicin C*Vinbastine (MV) in patients with metastatic breast cancer who have failed an antracicline containing regimen: preliminary results of a randomized phase III study, Oncology, 11, 25 Wilson, 1994, Paclitaxel in doxorubicin-refractary breast cancer: A phase I/II trial of 96 hour infusion, J Clin Onc, 12, 1621, 10.1200/JCO.1994.12.8.1621 Seidman, 1995, Paclitaxel as second and subsequent therapy for metasytatic breast cancer: Activity independent of prior anthraci-cline response, J Clin Onc, 13, 1621, 10.1200/JCO.1995.13.5.1152 Paridaens R, Bruning P, Klinj J; Gamucci T; Biganzoli L; Van Vreckem A; et. al.: An EORTC crossover trial comparing single-agent Taxol and doxorubicine as first and second line chemotherapy in advanced breast cancer. Proc Am Soc Clin Oncol 1997; Abstr 539. Ravdin, 1995, Phase II trial of docetaxel in advanced anthraciclin-resistant or antracenodione-resistant breast cancer, J. Clin. Oncol, 13, 2879, 10.1200/JCO.1995.13.12.2879 Valero, 1995, Phase II trial of docetaxel: a new highly effective antineo-plastic agent in the management of patients with antraciclin-resistant metastatic breast cancer, J. Clin. Oncol, 13, 2886, 10.1200/JCO.1995.13.12.2886 Hudis, 1996, Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer, J. Clin. Oncol, 14, 58, 10.1200/JCO.1996.14.1.58 Trudeau, 1996, Docetaxel in patients with metastatic breast cancer: a Phase II study of the national Cancer Institute of Canada-Clinical Trials Group, J Clin Oncol, 14, 422, 10.1200/JCO.1996.14.2.422 Sledge GW Jr, Neuberg D, Ingle J, Martina S, Wood W. Phase III trial of doxorubicin (A) vs paclitaxel (T) vs doxorubicin+paclitaxel (A+T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial. Proc Am Soc Clin Oncol, 1997; A2 (2). Honig, 1996, Hormonal therapy and chemotherapi, 669 Perez, 1999, Current management of metastatic breast cancer, Semin. Oncol, 26, 1 Falkson, 1998, Eastern Cooperative Oncology Group Randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission followinginduction treatment, J Clin. Oncol.,, 16, 1669, 10.1200/JCO.1998.16.5.1669 Peters, 1996, Proc Am Soc Clin Oncol, 15, A149 Muss, 1991, Interrupted versus continuous chemotherapy in patients with metastatic breast cancer, N Eng J Med, 325, 1342, 10.1056/NEJM199111073251904 Falkson, 1992, Metastatic breast cancer: higher versus low dose maintenance treatment when only a partial response or a no change status is obained following doxorubicin induction treatment: an Eastern Cooperative Oncology Group study, Ann Oncol, 3, 768, 10.1093/oxfordjournals.annonc.a058337 Stadtmauer, 2000, for the Philadelphia Bone Marrow Transplant Group: Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metasta-tic breast cancer, N Eng J Med, 342, 1069, 10.1056/NEJM200004133421501